Wcn24-2260 a Randomized Controlled Trial of Allopurinol for CVD in Ckd: Study Population Characteristics

Hyperuricemia is associated with adverse cardiovascular disease (CVD) outcomes in chronic kidney disease (CKD). Despite short-term favourable modulation of CV function by hypouricemic agents in CKD, evidence on long-term benefits are lacking. Recent clinical trials have not shown benefit of allopurinol in delaying progression of CKD. However, these trials were not specifically designed to assess impact on CVD outcomes in CKD. In the present study, we are testing the hypothesis that compared to placebo, allopurinol would significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with CKD.